Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice

Clinical Medicine: Oncology

Volumn 2, Issue , 2008, Pages 491-499

  Sun, Li Chun ^a   Mackey, L Vienna ^a   Luo, Jing ^a   Fuselier, Joseph A ^a   Coy, David H ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Camptothecin; Metastasis; Somatostatin conjugate; Somatostatin receptor; Tumor growth

Indexed keywords

EID: 78650869781     PISSN: None     EISSN: 11779314     Source Type: Journal    
DOI: 10.4137/cmo.s970     Document Type: Article

References (42)

1. Huh, K.M., Min, H.S., Lee, S.C., Lee, H.G., Kim, S. and Park, K. 2008. A new hydrotropic block copolymer micelle system for aqueous solubilization of paclitaxel. Journal of Controlled Release, 126:122-9.
2. Bencini, M., Ranucci, E., Ferruti, P., Trotta, F., Donalisio, M., Cornaglia, M. et al. 2008. Preparation and in vitro evaluation of the antiviral activity of the Acyclovir complex of a beta-cyclodextrin/ poly(amidoamine) copolymer. Journal of Controlled Release, 126:17-25.
3. Lee, L.Y., Wang, C.H. and Smith, K.A. 2008. Supercritical antisolvent production of biodegradable micro- and nanoparticles for controlled delivery of paclitaxel. Journal of Controlled Release, 125:96-106.
4. Haley, B. and Frenkel, E. 2008. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol., 26:57-64.
5. Wissing, S.A., Kayser, O. and Muller, R.H. 2004. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev., 56:1257-72.
6. Sengupta, S., Eavarone, D., Capila, I., Zhao, G., Watson, N., Kiziltepe, T. et al. 2005. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature, 436:568-72.
7. Guillemard, V. and Saragovi, H.U. 2001. Taxane-Antibody Conjugates Afford Potent Cytotoxicity, Enhanced Solubility, and Tumor Target Selectivity1. Cancer Res., 61:694-9.
8. Hsieh, F.Y., Tengstrand, E., Lee, J.W., Li, L.Y., Silverman, L., Riordan, B. et al. 2007. Drug safety evaluation through biomarker analysis-A toxicity study in the cynomolgus monkey using an antibody-cytotoxic conjugate against ovarian cancer. Toxicol. Appl. Pharmacol., 224:12-8.
9. Sun, L.C., Fuselier, J.A. and Coy, D.H. 2004. Effects of camptothecin conjugated to a somatostatin analog vector on growth of tumor cell lines in culture and related tumors in rodents. Drug Deliv., 11:231-8.
10. Kiaris, H., Schally, A.V., Nagy, A., Szepeshazi, K., Hebert, F. and Halmos, G. 2001. A targeted cytotoxic somatostatin (SST) analogue, AN.-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. Eur. J. Cancer, 37:620-8.
11. Moody, T.W., Fuselier, J.A., Coy, D.H., Mantey, S., Pradhan, T., Nakagawa, T. et al. 2005. Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells. Peptides, 26:1560-6.
12. Moody, T.W., Mantey, S.A., Pradhan, T.K., Schumann, M., Nakagawa, T., Martinez, A. et al. 2004. Development of high affinity camptothecinbombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J. Biol. Chem., 279:23580-9.
13. Sun, L.C. and Coy, D.H. 2008. Cytotoxic conjugates of peptide hormones for cancer chemotherapy. Drugs of the Future, 33:217-23.
14. Reubi, J.C. 2003. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev., 24:389-427.
15. Kohn, K.W. and Pommier, Y. 2000. Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors. Ann. N.Y. Acad. Sci., 922:11-26.
16. O'Leary, J. and Muggia, F.M. 1998. Camptothecins: a review of their development and schedules of administration. Eur. J. Cancer, 34:1500-8.
17. Moody, T.W., Sun, L.C., Mantey, S.A., Pradhan, T., Gonzales, N., Coy, D.H. et al. 2006. In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J. Pharmacol. Exp. Ther., 318:1265-72.
18. Engel, J.B., Schally, A.V., Halmos, G., Baker, B., Nagy, A. and Keller, G. 2005. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Cancer, 104:1312-21.
19. Engel, J.B., Schally, A.V., Halmos, G., Baker, B., Nagy, A. and Keller, G. 2005. Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocr. Relat. Cancer., 12:999-1009.
20. Keller, G., Schally, A.V., Gaiser, T., Nagy, A., Baker, B., Halmos, G. et al. 2005. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. Eur. J. Cancer., 41:2196-202.
21. Buchholz, S., Keller, G., Schally, A.V., Halmos, G., Hohla, F., Heinrich, E. et al. 2006. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormonereleasing hormone and their combinations. PNAS, 103:10403-7.
22. Fujita, T., Yamaji, Y., Sato, M., Murao, K. and Takahara, J. 1994. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. Life Sci., 55:1797-806.
23. Taylor, J.E., Theveniau, M.A., Bashirzadeh, R., Reisine, T. and Eden, P.A. 1994. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides, 15:1229-36.
24. Denzler, B. and Reubi, J.C. 1999. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer, 85:188-98.
25. Sun, L.C., Luo, J., Mackey, L.V., Fuselier, J.A. and Coy, D.H. 2007. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer Let., 246:157-66.
26. Sun, L.C., Vasilevich, N.I., Fuselier, J.A., Hocart, S.J. and Coy, D.H. 2004. Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design. Bioorg. Med. Chem. Lett, 14:2041-6.
27. Pradhan, T.K., Katsuno, T., Taylor, J.E., Kim, S.H., Ryan, R.R., Mantey, S.A. et al. 1998. Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur. J. Pharmacol., 343:275-87.
28. Liu, C., Chen, J., Kuei, C., Sutton, S., Nepomuceno, D., Bonaventure, P. et al. 2005. Relaxin-3/insulin-like peptide 5 chimeric peptide, a selective ligand for G protein-coupled receptor (GPCR)135 and GPCR142 over leucine-rich repeat-containing G protein-coupled receptor 7. Mol. Pharmacol., 67:231-40.
29. Anthony, C.T., Hughey, S., Lyons, J., Weiss, S., Hornick, C.A., Drouant, G.J. et al. 2004. The effect of drug dose and drug exposure time on the binding, internalization, and cytotoxicity of radiolabeled somatostatin analogs. J. Surg. Res., 119:1-13.
30. Panetta, R. and Patel, Y.C. 1995. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sciences, 56:333-42.
31. Kuperwasser, C., Dessain, S., Bierbaum, B.E., Garnet, D., Sperandio, K., Gauvin, G.P. et al. 2005. A Mouse Model of Human Breast Cancer Metastasis to Human Bone. Cancer Res., 65:6130-8.
32. Watson, J.C., Balster, D.A. and Gebhardt, M.B. 2001. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br. J. Cancer, 85:266-72.
33. Szepeshazi, K., Schally, A.V., Halmos, G., Sun, B., Hebert, F., Csernus, B. et al. 2001. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. Clin. Cancer Res., 7:2854-61.
34. Nagy, A., Schally, A.V. and Halmos, G. 1998. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. PNAS, 95:1794-9.
35. Sun, L.C., Luo, J., Mackey, L.V., Fuselier, J.A. and Coy, D.H. 2007. Effects of camptothecin on tumor cell proliferation and angiogenesis when coupled to a bombesin analog used as a targeted delivery vector. Anticancer Drugs, 18:341-8.
36. Bezerra, Y., Fuselier, J.A., Peyman, G.A., Oner, H., Drouant, G. and Coy, D.H. 2005. Study of inhibitory effects of an antiangiogenic somatostatin-camptothecin conjugate on laser-induced choroidal neovascularization in rats. Retina, 25:345-54.
37. Moody, T.W., Mantey, S.A., Fuselier, J.A., Coy, D.H. and Jensen, R.T. 2007. Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells. Peptides, 28:1883-90.
38. Langer, M., Kratz, F., Rothen-Rutishauser, B., Wunderli- Allenspach, H. and Beck-Sickinger, A.G. 2001. Novel peptide conjugates for tumor-specific chemotherapy. J. Med. Chem., 44:1341-8.
39. O'Dorisio, M.S., Chen, F., O'Dorisio, T.M., Wray, D. and Qualman, S.J. 1994. Characterization of somatostatin receptors on human neuroblastoma tumors. Cell Growth Differ., 5:1-8.
40. Qin, Y., Ertl, T., Groot, K., Horvath, J., Cai, R.Z. and Schally, A.V. 1995. Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate. Int. J. Cancer, 60:694-700.
41. Evers, B.M., Townsend, Jr. C.M., Upp, J.R., Allen, E., Hurlbut, S.C., Kim, S.W. et al. 1991. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology, 101:303-11.
42. Ludvigsen, E., Stridsberg, M., Taylor, J.E., Culler, M.D., Oberg, K. and Janson, E.T. 2004. Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells. Med. Oncol., 21:285-95.